14.38
price down icon0.35%   -0.05
after-market アフターアワーズ: 14.38
loading
前日終値:
$14.43
開ける:
$14.39
24時間の取引高:
287.73K
Relative Volume:
0.44
時価総額:
$584.05M
収益:
-
当期純損益:
$-168.05M
株価収益率:
-2.8031
EPS:
-5.13
ネットキャッシュフロー:
$-146.15M
1週間 パフォーマンス:
+0.14%
1か月 パフォーマンス:
+4.89%
6か月 パフォーマンス:
+21.45%
1年 パフォーマンス:
-70.99%
1日の値動き範囲:
Value
$14.19
$14.74
1週間の範囲:
Value
$13.64
$14.74
52週間の値動き範囲:
Value
$9.12
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
名前
Keros Therapeutics Inc
Name
セクター
Healthcare (1161)
Name
電話
617-314-6297
Name
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
職員
163
Name
Twitter
Name
次回の収益日
2024-11-04
Name
最新のSEC提出書
Name
KROS's Discussions on Twitter

KROS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KROS
Keros Therapeutics Inc
14.38 586.08M 0 -168.05M -146.15M -5.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-10 ダウングレード BofA Securities Buy → Neutral
2025-01-21 ダウングレード Cantor Fitzgerald Overweight → Neutral
2025-01-17 ダウングレード Wedbush Outperform → Neutral
2024-12-16 ダウングレード Guggenheim Buy → Neutral
2024-12-16 繰り返されました Oppenheimer Outperform
2024-12-13 繰り返されました H.C. Wainwright Buy
2024-12-12 ダウングレード BTIG Research Buy → Neutral
2024-12-12 ダウングレード TD Cowen Buy → Hold
2024-12-12 ダウングレード William Blair Outperform → Mkt Perform
2024-11-05 開始されました Jefferies Buy
2024-10-24 開始されました Cantor Fitzgerald Overweight
2024-10-16 開始されました Scotiabank Sector Outperform
2024-09-23 開始されました Guggenheim Buy
2024-06-25 開始されました Oppenheimer Outperform
2024-02-21 開始されました William Blair Outperform
2023-12-08 開始されました Wells Fargo Overweight
2023-07-31 開始されました Wedbush Outperform
2023-07-26 開始されました BofA Securities Buy
2023-02-14 開始されました Cowen Outperform
2022-10-18 開始されました Truist Buy
2022-07-26 開始されました BTIG Research Buy
2020-12-08 繰り返されました H.C. Wainwright Buy
2020-05-04 開始されました H.C. Wainwright Buy
2020-05-04 開始されました Jefferies Buy
2020-05-04 開始されました Piper Sandler Overweight
2020-05-04 開始されました SVB Leerink Outperform
すべてを表示

Keros Therapeutics Inc (KROS) 最新ニュース

pulisher
Jul 24, 2025

How high can Keros Therapeutics Inc. stock price go in 2025Consistent high-performance stocks - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Is Keros Therapeutics Inc. a good long term investmentExplosive wealth accumulation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Keros Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Keros Therapeutics Inc. stockFast-track wealth growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Keros Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

(KROS) Trading Signals - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 18, 2025

Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times

Jul 17, 2025
pulisher
Jul 17, 2025

Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com

Jul 17, 2025
pulisher
Jul 16, 2025

Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat

Jul 09, 2025
pulisher
Jul 09, 2025

Trend Tracker for (KROS) - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 08, 2025

Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com

Jul 08, 2025
pulisher
Jul 06, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 06, 2025
pulisher
Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 17, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat

Jun 12, 2025
pulisher
Jun 11, 2025

Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga

Jun 10, 2025

Keros Therapeutics Inc (KROS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
大文字化:     |  ボリューム (24 時間):